1. Introduction {#s0005}
===============

Cells continuously secrete a large number of small molecules, macromolecules and nanovesicles into the extracellular space ([@b0315]). Nanovesicles (NVs) are submicron membrane-coated vesicles of diameter up to 1000 nm, in which they are released from all cell types and contain cellular components of their parent's cell ([@b0315]). Exosomes and microvesicles (MVs) are collectively known as extracellular vesicles (EVs), and they have an aqueous core surrounded by a lipid bilayer membrane ([@b0140]). EVs are considered as a new class of signal mediators, which allow the transport of nucleic acids, proteins, lipids and second messengers ([@b0315], [@b0140]). EVs play significant roles in genetic transfer, cytokine release, angiogenesis, transfer of cell receptors, and proteinase release ([@b0140]). Under activation, growth, apoptosis, senescence, shearing stress, oxidative stress and injury, cells release excessive amount of EVs ([@b0015], [@b0020]).

Most of cells including endothelial cells, immune cells, cancer cells, hematopoietic cells, platelets, and erythrocytes are able to secret EVs ([@b0090]). EVs are formed by budding of the plasma membrane through the dynamic redistribution of phospholipids ([@b0205]). MVs and exosomes are differing in the biogenesis, size, surface markers, and biological roles ([@b0090]). MVs are plasma membrane-derived vesicles with size range between 100 nm and 1000 nm. During their formation, MVs retain surface molecules from parent's cell as well as part of their cytosolic content ([@b0200]).

On the contrary, exosomes have size up to 150 nm and are derived from a cascade of the fusion between early and late endosomes, lysosomes, and others depending on their cellular source ([@b0090], [@b0200]). The fusion of multivesicular bodies with the plasma membrane allows the release of exosomes into the extracellular space. Exosomes are membranous structures with a lipid bilayer rich in phospholipids, proteins, cholesterol, ceramide, and sphingolipids ([@b0315]). EVs can circulate in the vascular network, where they can evade phagocytosis as well as they can participate in autocrine, paracrine and endocrine signaling ([@b0260]).

In healthy humans, circulating EVs are mainly derived from platelets and to a lesser extent leukocyte and endothelial cells. An increase of EVs biogenesis has been demonstrated in physiological and pathological conditions ([@b0195]). The vascular endothelium is one of the primary targets of circulating EVs; they contribute to the regulation of endothelial cell functions, coagulation and inflammation ([@b0195]). However, abnormal biogenesis of EVs leads to endothelial dysfunction and development of cardiovascular diseases ([@b0195]).

The biogenesis of EVs is an inherent property of the erythrocyte plasma membrane. In healthy individuals, erythrocytes derived nanovesicles (EDNVs) are present at basal levels ([@b0130]). However, aging, high intracellular calcium levels and oxidative stress are triggers of erythrocytes vesiculation and release of EVs. Oxidized erythrocytes (Oxi-Ery) released EVs rich in oxidized proteins, lipid peroxides, cholesterol and other oxidized substances. Oxi-Ery and EDNVs are engulfed by macrophages and smooth muscle cells resulted in foam cells formation, and this induced endothelial dysfunction and enhanced atherosclerotic process ([@b0030], [@b0305]). An increase in EVs release was observed in hypertension, thrombocytopenia, multiple sclerosis, sickle cell anemia, diabetes, and atherosclerosis ([@b0015], [@b0020]).

Biogenesis, secretion mechanisms as well as biological roles of EVs have not been fully reported. Furthermore, their physiological and pathological roles are still a matter for research. Therefore, this report overviews biogenesis, beneficial and detrimental effects of EVs focus on EDNVs as new modulators in vascular disease. We hope that the present review will increase the understanding of EV biology.

2. EVs biogenesis {#s0010}
=================

Under resting cellular conditions, phospholipids in the bilayer of plasma membrane are asymmetrically distributed. Phosphatidylcholine (PC) and sphingomyelin are mostly present in the outer leaflet ([@b0180]). However, phosphatidylserine (PS), phosphatidylethanolamine and phosphatidylinositides are mainly present in the inner layer. This dynamic distribution of phospholipids is maintained by enzymes such as ATPases, scramblases, and floppases ([@b0180]). Transient or irreversible redistribution of phospholipid(s) across the membrane bilayer has been shown to play important roles in cellular events ([@b0180]). For example exposure of cells to oxidative stress, infection, cell signals, apoptosis and other stimuli resulted in EVs biogenesis ([@b0260]). Calcium ions are key players in EVs biogenesis due to inactivation of flippase. However calcium ions activate floppase, scramblase, calpain and gelsolin. Calpain hydrolyzes actin binding proteins that decrease the association of actin with membranes glycoproteins. However, gelsolin is involving in the cleavage of the actin capping proteins. These events are inducing loss of phospholipid asymmetry and protein anchorage to the cytoskeleton is disrupted, resultant in membrane budding and EVs release ([@b0035]). EVs isolated from blood are rich in phosphatidylcholine, sphingomyelin and minor quantities of other phospholipids ([@b0035])*.* EVs are characterized by PS exposed on their outer surface and other component of the parent cell. [Fig. 1](#f0005){ref-type="fig"} shows biogenesis and release of exosome and MVs; it clears that MVs bud directly from the plasma membrane, whereas exosomes are formed by budding of early endosomes. Calcium ions are key player in EVs biogenesis.

3. Biological roles of EVs {#s0015}
==========================

In many biological systems, EVs are considered as important mediators of cell--cell communication to underpin physiological function ([@b0185]). Under physiological conditions, EVs are released from various cell types to act as cellular messenger ([@b0260], [@b0170]). EVs transfer the bioactive molecules to target cells; therefore, EVs can modulate various biological processes such as angiogenesis, growth, cell differentiation, immune functions, stress response, and senescence ([@b0260], [@b0170]).

The cellular uptake machinery of EV may depend on proteins and glycoproteins found on the surface of both the vesicle and the target cell ([@b0225]). Moreover, the presence of external PS is a key determinant of the interaction of EVs with target cells; also the oxidized lipids may play the same role ([@b0200]). Cellular entrance of EVs is mediated by clathrin-dependent endocytosis, caveolin-mediated uptake, lipid raft-mediated internalization and phagocytosis ([@b0225]).

EVs are involved in inflammation and homeostasis, blood coagulation and apoptosis ([@b0115]). In the nervous system, EVs transmit the information in the form of proteins to facilitate neural circuit function.

On contrary, EVs have several detrimental effects such as enhanced viral infection, neurodegeneration and tumorigenesis ([@b0185]). Abnormal level of circulating EVs was documented in varieties of human diseases such as atherosclerosis, acute myocardial infarction, diabetes, hypertension, acute ischemic stroke, hyperlipidemia, and metabolic syndrome ([@b0115], [@b0200]).

4. Erythrocytes-derived vesicles(EDNVs) {#s0020}
=======================================

Normal erythrocytes have flexible biconcave shape with a cell diameter microsize of 5--7 μm and a thickness of 2 μm. The main functions of erythrocytes are transport of oxygen and carbon dioxide, and release of adenosine triphosphate (ATP) and nitric oxide (NO). Moreover, erythrocytes carry significant enzymes and molecules involved in L-arginine/NO metabolic pathway ([@b0255]).

Erythrocytes are the major vesicle-secreting cells in the circulating blood ([@b0075]), during their life span, and erythrocytes lose approximately 20 % of their hemoglobin and membrane through vesiculation ([@b0005]). The erythrocyte vesicles are known as microvesicles, exovesicles, ectosomes, nanovesicles and microparticles ([@b0130]). Erythrocytes-derived nanovesicles (EDNVs) have average size approximately 100--200 nm with a lipid bilayer rich in phospholipids, proteins, cholesterol, lipid raft, hemoglobin and acetylcholinesterase ([@b0130], [@b0205]).

EDNVs biogenesis has been described as a part of erythrocytes senescence and also proposed as a part of an apoptosis-like process (eryptosis) in these cells. The release of EDNVs plays a protective role that allows erythrocytes to clear away dangerous molecules and prevent their early removal from circulation ([@b0295]). Therefore, EDNVs act as a self-protective mechanism for removal of dangerous molecules formed during erythrocytes life span ([@b0320]). EDNVs were demonstrated in ischemia, shearing stress, cardiovascular diseases, hematological disorders and diabetes ([@b0020]).

An increase of intracellular calcium levels leads to disruption membrane asymmetry with concomitant biogenesis of EDNVs ([@b0130]). Additionally, depletion of ATP depletion and exposure to membranotropic and hemolytic agents trigger NVs release from erythrocytes ([@b0075], [@b0205]). As well, morphological alterations, storage conditions, arachidonic acid, lysophosphatidic acid, and loss of deformability propagate erythrocytes vesiculation ([@b0045]).

Oxidative stress and heavy metals exposure potentiate NVs shedding from erythrocytes due to depletion of antioxidant defense ([@b0130], [@b0240]). The inhibition of EDNVs biogenesis by antioxidants confirmed role of oxidative stress in stimulation of EVs production ([@b0115]). Erythrocytes vesiculation is associated with protein oxidation, and lipid peroxidation leading to a loss of deformability ([@b0115]). Similarly in many cells, EDNVs biogenesis triggered calcium concentrations that activate calpain, scramblase, and flippase ([@b0180]).

4.1. Mechanisms of EDNVs biogenesis {#s0025}
-----------------------------------

Three mechanisms have been proposed to explain EDNVs biogenesis, the eryptosis model, the band 3 clustering and oxidative stress. The eryptosis mechanism is similar to apoptosis of nucleated cells in response to various stresses but applied to erythrocytes ([@b0295]). Thus, a rise of ionic calcium influx through alteration of nonspecific cation channels leads to activation of calpain, scramblase and floppase; however, flippase was inactivated ([@b0035])*.* This resulted in disruption of phospholipid asymmetry and release of NVs. In band 3 clustering mechanism hemoglobin oxidation leads to hemichrome formation, followed by aggregation of band 3 multimers, degradation of cytoskeletal proteins and modification of band 3 phosphorylation ([@b0295]). In oxidative stress hypothesis, reactive species induce binding of hemoglobin to band 3, activation of calcium channels, and phosphorylation of proteins and aggregation of band 3 ([@b0295]). This hypothesis of erythrocytes vesiculation has been reinforced by the postulation of a study demonstrated that antioxidants addition inhibits NVs biogenesis ([@b0285]). [Fig. 2](#f0010){ref-type="fig"} shows proposed mechanism of oxidative stress induced erythrocyte vesiculation.

5. Biological roles of EDNVs {#s0030}
============================

In the past, EVs were considered as a garbage basket for removing unwanted materials as an integrated machinery of the lysosomal system. However, more recent data support the role of NVs in cellular homeostasis ([@b0090]). Various studies have suggested the importance of NVs in numerous cellular processes ([@b0130]). EDNVs are produced as a machinery to prevent premature erythrocyte removal by reticuloendothelial system. Therefore, these NVs protect erythrocytes via removal of complement attack complex, band 3 antigens, nonfunctional hemoglobin and other unwanted membrane-associated elements ([@b0115]).

5.1. EDNVs and oxidative stress {#s0035}
-------------------------------

Normally, erythrocytes are provided with antioxidant molecules such as glutathione, thioredoxin, ascorbic acid and vitamin E. Furthermore, they contain superoxide dismutase, catalase, glutathione peroxidase, thioredoxin reductase, glutathione reductase, and methemoglobin reductase ([@b0145], [@b0215]). Therefore, functional erythrocytes act as vascular guardian by scavenging reactive oxygen species (ROS) generated in itself, circulated blood, and vascular cells ([@b0215]). The decrease of erythrocytes antioxidant capacity resulted in oxidative stress and NO inactivation. In such cases, erythrocytes are labeled as key player in many diseases particularly cardiovascular disease ([@b0085]).

It has been reported that EDNVs are one of the priming causes of respiratory burst ([@b0130]), which is characterized by neutrophils activation with production of excessive amount of ROS. This is attributed to NVs having NADP oxidase subunits ([@b0200]). Moreover, [@b0105], reported that EVs upregulate NADPH-oxidase expression. Respiratory burst causes plethora of changes in cytoskeleton and cell membrane asymmetry resulted in formation of Oxi-ERY ([@b0215]). Oxi-ERY is rigid and undergoes hemolysis releasing cholesterol, lipids peroxidation product, aggregated protein and iron. All of them are potent stimulator of vascular cellular damage ([@b0320]). Therefore, Oxi-ERY and EDNVs act as dangerous bullets to vascular cells and trigger the damaging process ([@b0215]).

5.2. EDNVs and inflammation {#s0040}
---------------------------

EVs releases stimulate cell--cell interaction, adhesion molecule expression, cytokine release and increased macrophage differentiation ([@b0200]). The main components of erythrocyte membrane are phospholipids and cholesterol ([@b0305]). Erythrocyte membranes are richer in cholesterol than other cell in the body; subsequently, EDNVs are enriched in cholesterol, lipid raft, membrane proteins and hemoproteins ([@b0205]). The crystallization of cholesterol obtained from erythrocyte membrane may induce inflammatory reactions; furthermore, iron can act as a catalyst for ROS production ([@b0215]), that produce tissue damage and initiate extra inflammatory reactions ([@b0220]). Moreover, hemoglobin released from erythrocyte's hemolysis activates the pro-inflammatory transcription factor ([@b0220]). Phospholipase A~2~ hydrolyzes EDNVs phospholipids resulted in production of inflammatory mediators ([@b0005]). Also, NVs activate neutrophils that release myeloperoxidase as main source of ROS ([@b9000]). Altogether propagate vascular inflammation that accelerates the development of coronary heart diseases.

5.3. EDNVs and NO homeostasis {#s0045}
-----------------------------

NVs might exert beneficial or deleterious effects for the vascular wall depending on their cellular origin ([@b0265]). Additionally, [@b0105], reported that EVs have contradictory effects on NO biology, and EVs decrease NO bioavailability by reducing the activity of endothelial NO synthase. However, EVs induced up-regulation of inducible NO synthase resulting in an over production of NO. Therefore, EVs can induce endothelial dysfunction by enhancement of ROS production that reduces NO bioavailability ([@b0115], [@b0100], [@b0035]). Similarly, it has been demonstrated that NVs disrupt NO homeostasis by oxidative stress mediated mechanism. Moreover, EDNVs are hemoglobin containing vesicles or hemoglobin devoid of vesicles, both vesicles enhanced NO inactivation ([@b0075]). It has been reported that, EDNVs scavenge NO faster than intact erythrocytes ([@b0115]). Therefore, EDNVs are vasoconstrictors, increased erythrocyte adhesion, enhanced endothelial damage and caused vaso-occlusions ([@b0040]).

Erythrocytes vesiculation was associated with releasing of arginase-1 and hemoglobin into blood stream ([@b0075], [@b0325]). Release of erythrocyte's arginase was associated with lowered blood NO levels that induced erythrocyte dysfunction and endothelial damage ([@b0150]). Beside erythrocyte's arginase, their dimethylarginines and cationic amino transporter are important regulators of NO ([@b0330]). Asymmetric dimethylarginine competes with L-arginine transport; however, symmetric dimethylarginine interferes with L-arginine into the cells ([@b0065], [@b0085]).

5.4. EDNVs and thrombosis {#s0050}
-------------------------

EDNVs have procoagulant activity by participation in blood clotting process and enhancing thrombus formation ([@b0045]). These vesicles accelerate the coagulation cascade via conversion of prothrombin into thrombin ([@b0210]). The presence of PS on the surface of NVs provides a site for the assembly of the prothrombinase leading to formation of thrombin clot. Additionally, NVs can enhance clotting by inducing expression of clotting factors ([@b0070]). Adhesion of PS-expressing EDNVs to endothelial cells induced vaso-occlusion. Moreover, PS-exposed NVs provide sites for adhesion of platelets and neutrophils localized at the subendothelium. Taken together, PS-exposed EDNVs are new players in the development of thrombosis that is a risk factor in cardiovascular disease progression ([@b0240]).

5.5. EDNVs and foam cell formation {#s0055}
----------------------------------

Erythrocyte life span is limited by senescence with subsequent clearance of the aged erythrocytes, prior to senescence; they undergo suicidal death or eryptosis ([@b0175]). Phospholipid asymmetry is maintained throughout the life span of erythrocytes. Once the cell enters into eryptotic stage, PS was exposed on their outer surface and acted as a marker for macrophages to engulf aged erythrocytes; therefore, PS acts as signal for eryptosis and erythrophagocytosis ([@b0155]). Eryptosis shares other hallmarks of apoptosis, such as cell shrinkage, cell membrane blebbing and scrambling leading to PS exposure at the cell surface ([@b0175]). EDNVs-PS acts as an "eat me" marker for macrophages for removing damaged erythrocytes ([@b0320]). Therefore, reticuloendothelial system removes the PS-exposing nanovesicles instead of their parent's erythrocyte ([@b0320]).

Under oxidative stress erythrocytes are prone to subsequent vesiculation and production of NVs ([@b0030]). The surface of Oxi-Ery is flagged by PS exposure on the outer leaflets. Therefore, they are recognized by macrophage scavenger receptors ([@b0305]). This evokes foam cell formation ([@b0280]) and stimulates smooth muscle cell migration, which contributes to the progression of atherosclerosis ([@b0280]). The erythrocyte membrane is richer in cholesterol than other cells; therefore, intracellular free cholesterol accumulation is increased that triggers foam cells formation ([@b0305]). Moreover, NVs stimulate inflammatory responses and growth of necrotic core ([@b0200]). Consequently, NVs contribute to the progression of atherosclerosis ([@b0115]).

6. Isolation and detection of EVs {#s0060}
=================================

EVs separation is a major focus in the field of EVs research. The isolation processes of EVs include numerous sequential centrifugation steps with increasing centrifugal force. Thus size and density properties of EVs are used for the separation of EVs from other blood components. Initially, low-speed steps (300--500*g*) are applied to remove cells ([@b0275]). This is followed by higher speeds in the range of 10,000--20,000*g*, to remove cellular debris and to isolate larger EVs \> 100 nm. Finally, one or more ultracentrifugation steps are applied to pellet the smallest EVs, using centrifugal forces in the range of 100,000--200,000*g* ([@b0275]).

It is also possible to combine the ultracentrifugation with a density gradient, or affinity purification. The choice of the isolation procedure may have a considerable effect on the downstream analyses of EVs. In addition to the isolation, the pre-analytical procedures such as choice of anticoagulant, processing temperature and storage before analysis may affect detection and characterization of NVs ([@b0275]).

Characterization of NVs with regard to size, morphology, concentration, biochemical composition and cellular origin has been documented ([@b0115]). NVs surface markers allow identification and quantitation, although marker density must be sufficient to allow detection. Moreover, biochemical determinations of molecular components can allow enumeration in isolated EVs preparations ([@b0250]).

Assays of functional activity have also been used for certain NVs subpopulations. The presence of nucleic acids provides another means to measure NVs using dyes that interact with DNA and RNA. The use of nucleic acid-binding dyes can provide information on the cell of origin of EVs ([@b0250]). Furthermore, EVs can be characterized by the detection of the different cell surface antigens. These antigens reflect their origin and activation method ([@b0035]). Also, characterization of EVs requires complementary biochemical, mass spectrometry, and imaging techniques ([@b0270]). Isolation methods, centrifugation protocols, time and temperature between phlebotomy and initial centrifugation, thaw and freezing, reagent compositions, instrument settings and calibration affect EVs analysis ([@b0135]).

The common technologies widely applied for the detection of EVs include electron microscopy, flow cytometry, dynamic light scattering, and nanoparticle tracking analysis ([@b0140]). The frequently used techniques in EVs detection are flow cytometry analysis, and enzyme-linked immunoassays. As well, fluorescence-based antibody array system can rapidly identify the cell origin of EVs. Despite several techniques are used in EVS characterization, the measurement of NVs still has standardization problems ([@b0265]).

7. Application of NVs {#s0065}
=====================

NVs are normally released from the organs into the blood stream and can be detected in the peripheral blood. Moreover, they can be detected in the urine and other body fluids ([@b0090]). The circulating basal levels of EVs can be found in the blood of healthy individuals. However, an increase in their release may be considered as biomarker of biological changes; hence, they have possible diagnostic values ([@b0015]). Although some of these NVs populations occur in the blood of healthy individuals and patients, there are obvious changes in number, cellular origin, and composition in various disease states ([@b0090]).

7.1. NVs as biomarkers for diseases {#s0070}
-----------------------------------

The release of NVs has been shown from endothelial cells, vascular smooth muscle cells, platelets, white blood cells, erythrocytes, neurons and cancer cells ([@b0310]). The concentration and composition of NVs depend upon their cellular origin and the stimuli that trigger their production ([@b0135]). Therefore, circulating NVs can be used as sensitive and specific biomarkers for diseases. NVs have been investigated for prognosis in cardiovascular diseases, paroxysmal nocturnal hemoglobinuria, heparin induced thrombocytopenia, sickle cell disease and sepsis ([@b0135]). Particularly, an increase of circulating NVs originating from blood cells was demonstrated as marker for atherosclerosis exacerbation ([@b0050]). Furthermore, NVs were used as biomarker for neurodegenerative disorders, diabetes, rheumatic diseases, cancer and other diseases ([@b0245], [@b0050]). NVs contain cytokines that can be used as indicator for inflammatory response ([@b0070]). Increased level of EVs was documented in patients with neurological diseases ([@b0060]).

7.2. NVs as smart drug delivery tool {#s0075}
------------------------------------

### 7.2.1. NVs as drug delivery cargo {#s0080}

EVs are promising biological drug delivery nano-carriers, and they could overcome restrictions of synthetic nanocarriers ([@b0160]). They are well tolerated and could be delivering hydrophilic, hydrophobic drugs as well as biopharmaceuticals; therefore, EVs are suitable for the development of drug delivery cargo ([@b0160]). EVs have ability to permeate plasma membrane of target cells, have an intrinsic ability to home target tissues, and their membrane can be amenable to improve specific cell targeting ([@b0160]). Consequently, NVs can deliver various drugs to specific tissues, thereby reducing therapeutic doses and decreasing side effects ([@b0290]). EVs are vectors which transfer therapeutic agents that maintain cell homeostasis, cell repair, and cardioprotective drugs. Hence, EVs have beneficial effects in the field of cardiovascular medicine and regenerative therapy ([@b0095]). Additionally, drug loaded NVs can be across blood--brain barrier to deliver their cargo to neurons ([@b0165]). These biological carriers overcoming immunogenicity were associated with liposomes, nanoparticles and viral vectors ([@b0095]).

By mimicking EVs, artificial NVs are constructed from phospholipid precursors to form phospholipid bilayer membranous nanovesicles. They have amphipathic and biocompatibility properties. Artificial NVs are member of smart drug delivery systems, improve solubility, prolonged action, and reduced drug toxicity and increase cellular accumulation of drugs ([@b0095]). Despite, artificial NVs are attractive tools for drug delivery; they still have some biocompatibility problems such opsonization and recognition by immune system as foreign bodies ([@b0160], [@b0080]). Therefore, they could be coated with hydrophilic polymers to reduce their recognition by opsonins and clearance by recto-endothelial system ([@b0160]). This approach is partially solving the problem of nanoparticle opsonization. The production of biomimics of nanoparticle stealth is novel challenge in the field of drug delivery. EDNVs-coated nanoparticles for long-circulating cargo delivery may resolve the problem of nanoparticles opsonization ([@b0120]).

### 7.2.2. EDNVs as nanoparticles stealth {#s0085}

In vivo administration of nanoparticles larger than 100 nm is opsonized and quickly eliminated from the circulation via the reticuloendothelial system ([@b0055]). Therefore, production of camouflaged nanoparticles for long-circulating cargo delivery may resolve the problem of nanoparticles opsonization ([@b0120]).

Erythrosomes are EDNVs, and they are biodegradable vesicles and non-immunogenic in autologous administration ([@b0120], [@b0110]). Nanoerythrosomes are prepared by extrusion of erythrocyte ghosts through filters of defined pore size. They are used as a novel drug delivery system and used as nanoparticles stealth to minimize nanoparticles clearance ([@b0120], [@b0110]).

Nanoparticles stealth can be achieved using bioinspired nanoparticles with biomimetic camouflage coating such erythrocytes, erythrocyte ghosts and EDNVs ([@b0025], [@b0235]). These biomimetic cargos have tremendous potential in drug delivery applications, as they provide the opportunity to actively inhibit the rapid immune clearance of their therapeutic cargo, thereby improving drug pharmacokinetics and therapeutic efficacy ([@b0125]). [Fig. 3](#f0015){ref-type="fig"} represents role of erythrocytes and EDNVs as drug delivery system and nanoparticle stealth.

Also, these cargos can be delivered to specific tissues such as intravascular drug delivery, liver, spleen, lungs and bone marrow as well as selective tumor targeting ([@b0230], [@b0235]).

7.3. NVs as target for therapeutic agents {#s0090}
-----------------------------------------

EVs are double weapon that has both valuable and unfavorable effects on the biological systems. Disruption of NVs biogenesis may elicit deleterious effects on cellular components. Consequently, approaches that minimize NVs biogenesis could represent novel therapeutic approach ([@b0195]). The design of NVs modulating therapy is based on inhibiting EVs biogenesis, inhibiting their cellular uptake, or inhibiting their active components ([@b0010]). Consequently, inhibition of ceramide biosynthesis decreases EVs biogenesis as well as GTPases inhibitors may inhibit EVs release. However, NVs cellular entrance is prohibited by blocking PS receptors and protein receptors on the receipt cells ([@b0010], [@b0225]). Moreover, [@b0225], listed several agents that inhibit EVs cellular entry such as heparin, chlorpromazine, amiloride, annexin-V, proton pump inhibitor and other agents ([@b0225]).

Statins have hypocholesterolemic effect and pleiotropic effects such as antioxidant, anti-proliferative, anti-thrombotic effects, inhibition of NADPH oxidase activity and inhibition of G-protein lipidation ([@b0300]). Inhibition of G-protein signaling by statins was proposed as EVs mechanism ([@b0190]). As well statins inhibit lipid raft mediated endocytosis ([@b0225]).

It is well demonstrated that an increases of intracellular calcium, ROS, and apoptotic events are common causes in NVs production by most cells ([@b0260], [@b0035]). In this regard, calcium antagonists and ROS scavengers may elicit inhibitory effect on cellular vesiculation. Calcium channel blockers are an example of agent that attenuates EVs biogenesis ([@b0195]). Moreover, therapy by renin angiotensin inhibitor led to a decrease in EVs level ([@b0100]). As well, lowering of oxidative stress lowered EVs level ([@b0195]). In this regard, [@b0115] reported that antioxidant therapy inhibits the NVs formation. Furthermore, reduction in oxidative stress resulted in decline of NVs biogenesis ([@b0100]). Likewise, [@b0285] demonstrated a significant decrease in EVs production by the addition of antioxidants to erythrocytes. [Fig. 4](#f0020){ref-type="fig"} displays the possible effect of therapeutic agents on NVs biogenesis.

It is important to emphasize that inhibition of EVs biogenesis could result in undesirable effects because EVs and their active components are important for the regulation of normal biological processes and other core cellular functions ([@b0010]).

8. Conclusion {#s0095}
=============

EVs transmit biological signals that can implicate in numerous physiological and pathological processes. EVs are released in body fluids and can be used as potential biomarkers for diagnosis, prognosis and monitoring of the therapeutic efficacy. EDNVs can mediate harmful effects such as thrombosis, inflammation, endothelial dysfunction atherosclerosis and vaso-occlusion. Calcium antagonist, antioxidant and statins are proposed agents that may modulate EVs biogenesis. Despite EDNVs appear as new culprit that affects vascular functions, they can be used as smart drug delivery tool.
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